Transcode Therapeutics (RNAZ) Total Liabilities (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Total Liabilities came in at $12.6 million in Q1 2026, up 335.74% YoY from $2.9 million in Q1 2025, and up 20.2% on a QoQ basis from $10.5 million in Q4 2025.
Transcode Therapeutics (RNAZ) Total Liabilities (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Total Liabilities data on file, last reported at $12.6 million in Q1 2026.
- Quarterly Total Liabilities rose 335.74% year-over-year to $12.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.6 million (up 335.74% YoY) and the FY2025 annual result came in at $10.5 million, up 12.94% from the prior year.
- Total Liabilities rose to $12.6 million in Q1 2026, from $10.5 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $12.6 million in Q1 2026 to a low of $1.7 million in Q2 2022.
- A 5-year average of $4.7 million and a median of $3.8 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities slumped 73.66% — and 2026, when it soared 335.74%.
- Tracing RNAZ's Total Liabilities over 5 years: stood at $4.3 million in 2022, then decreased by 18.83% to $3.5 million in 2023, then surged by 163.91% to $9.3 million in 2024, then grew by 12.94% to $10.5 million in 2025, then advanced by 20.2% to $12.6 million in 2026.
- The last three Total Liabilities figures came in at $12.6 million (Q1 2026), $10.5 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 10.03 Bn |
| 10 | Transcode Therapeutics | 2.80 Mn | 2.80 Mn | - | 12.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.64 Mn |
| Dec 31, 2025 | 10.52 Mn |
| Sep 30, 2025 | 3.80 Mn |
| Jun 30, 2025 | 2.12 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 9.31 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Mar 31, 2024 | 2.71 Mn |
| Dec 31, 2023 | 3.53 Mn |
| Sep 30, 2023 | 5.79 Mn |
| Jun 30, 2023 | 3.79 Mn |
| Mar 31, 2023 | 5.83 Mn |
| Dec 31, 2022 | 4.35 Mn |
| Sep 30, 2022 | 3.77 Mn |
| Jun 30, 2022 | 1.73 Mn |
| Mar 31, 2022 | 1.85 Mn |
| Dec 31, 2021 | 2.53 Mn |
| Sep 30, 2021 | 2.20 Mn |
| Jun 30, 2021 | 6.56 Mn |